Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry
- PMID: 28949063
- DOI: 10.1002/ejhf.964
Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry
Abstract
Aims: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.
Methods and results: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.
Conclusions: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.
Keywords: Beta-blockers; Chronic obstructive pulmonary disease; Heart failure; Hospitalization; Mortality; Registry.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.
Comment in
-
Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care.Eur J Heart Fail. 2018 Jan;20(1):111-113. doi: 10.1002/ejhf.986. Epub 2017 Sep 26. Eur J Heart Fail. 2018. PMID: 28949057 No abstract available.
Similar articles
-
The Management and Outcome of Hospitalized and Ambulatory Israeli Heart Failure Patients Compared to European Heart Failure Patients: Results from the ESC Heart Failure Long-Term Registry.Isr Med Assoc J. 2017 Apr;19(4):225-230. Isr Med Assoc J. 2017. PMID: 28480675
-
Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.Eur J Heart Fail. 2012 Apr;14(4):395-403. doi: 10.1093/eurjhf/hfs009. Epub 2012 Feb 2. Eur J Heart Fail. 2012. PMID: 22302663
-
Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.Eur J Heart Fail. 2016 Jul;18(7):840-8. doi: 10.1002/ejhf.519. Epub 2016 Apr 21. Eur J Heart Fail. 2016. PMID: 27098360
-
Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.J Am Coll Cardiol. 2007 Jan 16;49(2):171-80. doi: 10.1016/j.jacc.2006.08.046. Epub 2006 Dec 29. J Am Coll Cardiol. 2007. PMID: 17222727 Review.
-
Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease.JACC Heart Fail. 2019 Oct;7(10):823-833. doi: 10.1016/j.jchf.2019.05.009. Epub 2019 Sep 11. JACC Heart Fail. 2019. PMID: 31521680 Review.
Cited by
-
Heart failure prevalence in the general population: SOBOTA-HF study rationale and design.ESC Heart Fail. 2019 Oct;6(5):1077-1084. doi: 10.1002/ehf2.12496. Epub 2019 Jul 25. ESC Heart Fail. 2019. PMID: 31347289 Free PMC article.
-
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.Eur J Heart Fail. 2019 Mar;21(3):286-296. doi: 10.1002/ejhf.1351. Epub 2018 Dec 10. Eur J Heart Fail. 2019. PMID: 30537163 Free PMC article. Review.
-
Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease.Eur Heart J Suppl. 2021 Oct 8;23(Suppl E):E172-E176. doi: 10.1093/eurheartj/suab116. eCollection 2021 Oct. Eur Heart J Suppl. 2021. PMID: 34650380 Free PMC article.
-
Highlights in heart failure.ESC Heart Fail. 2019 Dec;6(6):1105-1127. doi: 10.1002/ehf2.12555. ESC Heart Fail. 2019. PMID: 31997538 Free PMC article. Review.
-
Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.Clin Med (Lond). 2020 Nov;20(6):551-559. doi: 10.7861/clinmed.2020-0359. Clin Med (Lond). 2020. PMID: 33199319 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous